Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Immunoproteasome inhibitor KZR-616 shows promise in phase I study

Nov. 22, 2017

Kaken Pharmaceutical evaluates novel prostanoid EP4 receptor antagonist for rheumatoid arthritis

Nov. 22, 2017

Full U.S. commercial launch for Zilretta

Nov. 21, 2017

Inception 1 discovers novel NADPH oxidase 4 inhibitors

Nov. 16, 2017

Galapagos's GLPG-1972 well tolerated in healthy volunteers

Nov. 16, 2017

Numerate receives grant from NIH to develop EZH2 inhibitor-coated orthopedic implants

Nov. 16, 2017

Boehringer Ingelheim's adalimumab biosimilar, Cyltezo, approved in E.U.

Nov. 15, 2017

Dosing begins in first-in-human phase Ib study of DEN-181

Nov. 15, 2017

Clinical progress reported for Pfizer's IRAK-4 inhibitor PF-06650833

Nov. 15, 2017

Phase I results reported for Bristol-Myers Squibb candidate for autoimmune diseases

Nov. 14, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...